Anaptysbio (ANAB) EBIT (2016 - 2026)

Anaptysbio (ANAB) has 11 years of EBIT data on file, last reported at -$34.6 million in Q1 2026.

• Quarterly EBIT fell 25.77% year-over-year to -$34.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.8 million (up 140.68% YoY) and the FY2025 annual result came in at $47.9 million, up 141.67% from the prior year.
• EBIT declined to -$34.6 million in Q1 2026, from $66.9 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $66.9 million in Q4 2025 to a low of -$44.4 million in Q1 2023.
• A 5-year average of -$22.4 million and a median of -$29.6 million in 2022 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT tumbled 5115.57% — and 2025, when it soared 791.84%.
• Tracing ANAB's EBIT over 5 years: stood at -$26.0 million in 2022, then tumbled by 62.23% to -$42.1 million in 2023, then surged by 77.05% to -$9.7 million in 2024, then jumped by 791.84% to $66.9 million in 2025, then plunged by 151.77% to -$34.6 million in 2026.
• The last three EBIT figures came in at -$34.6 million (Q1 2026), $66.9 million (Q4 2025), and $34.7 million (Q3 2025), per Business Quant data.